Patents & publications

As a result of our internal R&D programs and successful contribution to our clients projects, Enantia appears in more than 30 patent applications either as applicant or as inventor.

Apart from acting as a CRO, Enantia has become an active R&D player in the API arena developing its own projects. Thus Enantia has developed new chemical processes and API solid forms that have been patent protected and later commercialized through a range of agreements with our partners. The IP generated at Enantia represents interesting commercial opportunities in the fields of API manufacturing and lifecycle management.

A selected list of products for which Enantia has contributed to a patent filing can be found below.

Patent applications filed as a result of service projects:

• Quetiapine
• Sartans
• Delmopinol
• Montelukast
• Esomeprazole. Omeprezole resolution by co-crystallization process
• Sildenafil
• Salts of COX-inhibitors
• O-Demethylated-Tramadol co-crystals
• Linezolid
• Co-crystals of Tramadol
• Co-crystal of Celecoxib
• Metyrosine
• Erlotinib

Patent applications filed as a result of internal R&D projects:

• Gamma-Amino-vinyl sulphones (WO/2004/101504)
• Valsartan (WO/2006/067216 and WO/2007/071750)
• Adapalene (WO/2007/063522 and WO/2007/063523)
• New ligands for Pauson-Khand reaction (WO/2008/046950)
• Trans-(2R,4R)-4-Methylpipecolic acid (WO/2011/039290)
• Rivaroxaban (WO/2011/080341)
• Dabigatran etexilate (Not yet public)
• Aminodiphosphines as industrial chiral ligands for enantioselective hydrogenations (Not yet public)